AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 11.8% in January

AngioDynamics, Inc. (NASDAQ:ANGO - Get Free Report) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 882,000 shares, a drop of 11.8% from the December 31st total of 1,000,000 shares. Based on an average daily volume of 625,200 shares, the days-to-cover ratio is currently 1.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright lifted their price target on AngioDynamics from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday, January 10th.

AngioDynamics Stock Performance

Shares of ANGO stock traded down $0.06 on Tuesday, hitting $10.98. 492,182 shares of the stock traded hands, compared to its average volume of 1,044,804. The stock has a market capitalization of $444.36 million, a PE ratio of -1.95 and a beta of 0.60. The firm's 50-day moving average price is $9.81 and its two-hundred day moving average price is $8.11. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.07. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The company's quarterly revenue was down .1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.05) EPS. On average, equities research analysts anticipate that AngioDynamics will post -0.37 EPS for the current fiscal year.

Insider Transactions at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the transaction, the senior vice president now directly owns 41,817 shares of the company's stock, valued at $514,767.27. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 5.40% of the company's stock.

Institutional Investors Weigh In On AngioDynamics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quarry LP lifted its position in shares of AngioDynamics by 75.1% during the second quarter. Quarry LP now owns 6,047 shares of the medical instruments supplier's stock worth $37,000 after purchasing an additional 2,594 shares in the last quarter. R Squared Ltd purchased a new stake in AngioDynamics during the 4th quarter worth approximately $49,000. CWM LLC lifted its holdings in AngioDynamics by 981.3% during the 3rd quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier's stock worth $76,000 after buying an additional 8,832 shares in the last quarter. Mackenzie Financial Corp purchased a new position in AngioDynamics in the 2nd quarter valued at approximately $80,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new position in shares of AngioDynamics in the third quarter worth $86,000. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.